|
|
|
14.07.25 - 14:03
|
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804 and IL272092, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon's LSD1 inhibitor in clinical development for the treatment of psychiatric disorders....
|
|
|
25.06.25 - 14:03
|
ORYZON to Host Virtual KOL Event on July 9, 2025 (GlobeNewswire EN)
|
|
|
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat's Phase III PORTICO-2 trial in BPD...
|
|
|
23.06.25 - 14:03
|
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it has submitted the clinical trial protocol for its Phase III PORTICO-2 trial to the U.S. Food and Drug Administration (FDA) to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD). The PORTICO-2 trial builds upon the encouraging results observed in the previous PORTICO Phase IIb study, where vafidemstat demonstrated significant and clinically meaningful reductions in secondary endpoints measuring aggression and overall BPD improvement. Aggression is a key symptom domain in BPD that currently represents a major unmet medical need and will be the primary endpoint in PORTICO-2. Vafidemstat, an orally active LSD1 inhibitor with a novel epigenetic mechanism of action, has shown a favorable safety and tolerability profile across multip...
|
|
|
17.06.25 - 14:03
|
ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29 (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its Chief Scientific Officer, Dr. Jordi Xaus will be attending the 2025 Phelan-McDermid Syndrome Congress in Barcelona on June 26-29, which comprises the CureSHANK 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS2025) and the III Scientific Conference of the Spanish Phelan-McDermid Syndrome Association. Dr. Xaus will participate in a panel discussion within PMSDDS2025 entitled “Industry Perspectives Discussion”, as part of the morning session “Noncommercial & Commercial Clinical Trials and Business Considerations”, on June 27....
|
|
|
|
|
|
|
|
|
08.05.25 - 14:03
|
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project) (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the publication of the Spanish provisional resolution proposal for Med4Cure, the first Important Project of Common European Interest (IPCEI) aimed to support research, innovation, and the first industrial deployment of pharmaceuticals and healthcare products in Europe, awarding Oryzon a non-refundable grant of 13,263,794 € (approximately 15 million USD) for its VANDAM project. This amount corresponds to 64% of the total accepted budget (20.68 million €) for the VANDAM Project....
|
|
|
|
|
14.03.25 - 13:03
|
ORYZON to Provide Corporate Progress Updates at Several Events in March-April (GlobeNewswire EN)
|
|
|
MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in March-April....
|
|
|
|
|
28.02.25 - 15:18
|
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders′ Meeting (GlobeNewswire EN)
|
|
|
MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share capital) were at the Meeting, either in person or represented by proxy....
|
|
|
|
|
|
|
14.02.25 - 14:03
|
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of the Phase IIa REIMAGINE study, which evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD), were published online in Psychiatry and Clinical Neurosciences. A summary of the final data from this study had been previously released at the 2020 European Psychiatry Association (EPA) annual meeting....
|
|
|
27.01.25 - 15:33
|
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders′ Meeting (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, scheduled for February 28. Four new members will be added to the Board: Dr. Konstantinos Alataris, Dr. Pierre Beaurang, Dr. Montserrat Vendrell, and Luis Sánchez Quintana....
|
|
|
23.01.25 - 14:03
|
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon's potent and selective LSD1 inhibitor, in combination with azacitidine in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin (MCW)....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
